» Articles » PMID: 22114732

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

Overview
Journal PLoS One
Date 2011 Nov 25
PMID 22114732
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express nuclear androgen receptor (AR) and androgen regulated genes. We recently reported that C-terminal truncated constitutively active AR splice variants contribute to CRPC development. Since specific antibodies detecting all C-terminal truncated AR variants are not available, our aim was to develop an approach to assess the prevalence and function of AR variants in prostate cancer (PCa).

Methodology/principal Findings: Using 2 antibodies against different regions of AR protein (N- or C-terminus), we successfully showed the existence of AR variant in the LuCaP 86.2 xenograft. To evaluate the prevalence of AR variants in human PCa tissue, we used this method on tissue microarrays including 50 primary PCa and 162 metastatic CRPC tissues. RT-PCR was used to confirm AR variants. We observed a significant decrease in nuclear C-terminal AR staining in CRPC but no difference between N- and C-terminal AR nuclear staining in primary PCa. The expression of the AR regulated proteins PSA and PSMA were marginally affected by the decrease in C-terminal staining in CRPC samples. These data suggest that there is an increase in the prevalence of AR variants in CRPC based on our ability to differentiate nuclear AR expression using N- and C-terminal AR antibodies. These findings were validated using RT-PCR. Importantly, the loss of C-terminal immunoreactivity and the identification of AR variants were different depending on the site of metastasis in the same patient.

Conclusions: We successfully developed a novel immunohistochemical approach which was used to ascertain the prevalence of AR variants in a large number of primary PCa and metastatic CRPC. Our results showed a snapshot of overall high frequency of C-terminal truncated AR splice variants and site specific AR loss in CRPC, which could have utility in stratifying patients for AR targeted therapeutics.

Citing Articles

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.

Haffner M, Morris M, Ding C, Sayar E, Mehra R, Robinson B Clin Cancer Res. 2024; 31(3):466-478.

PMID: 39589343 PMC: 11790385. DOI: 10.1158/1078-0432.CCR-24-2061.


LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.

Ning S, Armstrong C, Xing E, Leslie A, Gao R, Sharifi M Cancer Res. 2024; 84(21):3617-3628.

PMID: 39088701 PMC: 11534543. DOI: 10.1158/0008-5472.CAN-24-0440.


Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.

Asemota S, Effah W, Young K, Holt J, Cripe L, Ponnusamy S Cell Rep. 2023; 42(12):113461.

PMID: 37979170 PMC: 10872270. DOI: 10.1016/j.celrep.2023.113461.


Therapeutic implications of cancer stem cells in prostate cancer.

Banerjee P, Kapse P, Siddique S, Kundu M, Choudhari J, Mohanty V Cancer Biol Med. 2023; 20(6).

PMID: 37282627 PMC: 10291985. DOI: 10.20892/j.issn.2095-3941.2022.0714.


Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer.

Kang B, Mottamal M, Zhong Q, Bratton M, Zhang C, Guo S Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242518 PMC: 10222209. DOI: 10.3390/ph16050735.


References
1.
Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

2.
Wu J, Odman A, Higgins L, Haugk K, Vessella R, Ludwig D . In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005; 11(8):3065-74. DOI: 10.1158/1078-0432.CCR-04-1586. View

3.
Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

4.
Montgomery R, Mostaghel E, Vessella R, Hess D, Kalhorn T, Higano C . Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68(11):4447-54. PMC: 2536685. DOI: 10.1158/0008-5472.CAN-08-0249. View

5.
Guo Z, Yang X, Sun F, Jiang R, Linn D, Chen H . A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69(6):2305-13. PMC: 2672822. DOI: 10.1158/0008-5472.CAN-08-3795. View